The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [14C]-BI 425809 in Healthy Males

Ute Burkard, Michael Desch, Yury Shatillo, Glen Wunderlich, Salome Rebecca Mack, Christina Schlecker, Aaron M Teitelbaum, Pingrong Liu, Tom S Chan, Ute Burkard, Michael Desch, Yury Shatillo, Glen Wunderlich, Salome Rebecca Mack, Christina Schlecker, Aaron M Teitelbaum, Pingrong Liu, Tom S Chan

Abstract

BACKGROUND AND OBJECTIVES: BI 425809, a novel glycine transporter-1 inhibitor, may ameliorate cognitive deficits in schizophrenia. The objectives of the studies were: to assess absolute bioavailability of oral BI 425809 compared with intravenous (IV) microtracer infusion (study 1), and to determine the mass balance, distribution, metabolism, and excretion of BI 425809 (study 2).

Methods: These were Phase I, open-label, non-randomized, single-period, single-arm studies in healthy males. Study 1 administered a single oral dose of unlabeled BI 425809 25 mg, then an IV microtracer infusion of [14C]-BI 425809 30 µg. In study 2, participants received an oral dose of [14C]-BI 425809 25 mg containing [14C]-labeled (dose: 3.7 megabecquerel (0.41 mSv)) and unlabeled drug. Safety was assessed.

Results: In study 1 (n = 6), the absolute bioavailability of a 25 mg tablet of BI 425809 in a fasted state was 71.64%. The geometric mean dose-normalized maximum plasma concentration was approximately 80% lower after oral administration versus IV dose. In study 2 (n = 6), the total recovery of [14C]-BI 425809 was 96.7%, with ~ 48% of [14C]-radioactivity excreted in urine and ~ 48% excreted in feces. Among the labeled drug in urine, ~ 45% of the amount excreted was composed of BI 425809 (17.4%) and two metabolites (BI 758790, 21.0%; BI 761036, 5.9%). In feces, < 1% of BI 425809 was excreted as unchanged drug. In both studies, BI 425809 was generally well tolerated.

Conclusions: After normalization, the absolute bioavailability of tablet-form BI 425809 was 71.64%. The total recovery of [14C]-BI 425809 25 mg was high (96.7%), with low intraindividual variability and similar amounts excreted in urine and feces. CLINICALTRIALS.

Gov identifiers: NCT03783000 and NCT03654170.

Conflict of interest statement

UB, MD, YS, SRM, and CS are employees of Boehringer Ingelheim Pharma GmbH; GW, AMT, PL, and TSC are employees of Boehringer Ingelheim Pharmaceuticals Inc.

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Figures

Fig. 1
Fig. 1
a Study 1 design: absolute bioavailability of BI 425809, and b study 2 design: mass balance recovery of BI 425809. PK pharmacokinetic
Fig. 2
Fig. 2
Individual and gMean drug plasma concentration after single a oral administration of BI 425809 25 mg or b intravenous (IV) infusion of labeled [14C]-BI 425809 3 µg. gMean geometric mean
Fig. 3
Fig. 3
a Total recovery of [14C]-BI 425809 25 mg in urine and feces; b cumulative [14C]-radioactivity excreted in urine; c cumulative [14C]-radioactivity excreted in feces. a Shows the gMean and gCV; b, c show the gMean plus individual participant data. Fe fraction excreted
Fig. 4
Fig. 4
gMean drug concentration time profiles of [14C]-BI 425809 25 mg and its metabolites in plasma. AUC area under curve, AUC0–tz time interval from 0 to the last quantifiable data point, gMean geometric mean
Fig. 5
Fig. 5
Comparison of [14C]-BI 425809 25 mg and its metabolites excreted in urine. The data shown are from a single participant. Ae0–366 amount excreted up to 366 h

References

    1. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158(9):1367–1377. doi: 10.1176/appi.ajp.158.9.1367.
    1. Hu N-W, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav. 2012;100(4):855–862. doi: 10.1016/j.pbb.2011.04.013.
    1. Hashimoto K. Glycine transport inhibitors for the treatment of schizophrenia. Open Med Chem J. 2010;4:10–19.
    1. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100(4):665–677. doi: 10.1016/j.pbb.2011.03.023.
    1. Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol (San Diego, Calif). 2016;76:351–382. doi: 10.1016/bs.apha.2016.01.006.
    1. Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, et al. Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: translational studies. Clin Transl Sci. 2018;11(6):616–623. doi: 10.1111/cts.12578.
    1. Rubio MD, Drummond JB, Meador-Woodruff JH. Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol Ther (Seoul) 2012;20(1):1–18. doi: 10.4062/biomolther.2012.20.1.001.
    1. Lakhan S, Caro M, Hadzimichalis N. NMDA receptor activity in neuropsychiatric disorders. Front Psychiatry. 2013;4:52. doi: 10.3389/fpsyt.2013.00052.
    1. Lane H-Y, Chang L-H, Liu Y-C, Chiu C-C, Tsai G. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62:1196–1204. doi: 10.1001/archpsyc.62.11.1196.
    1. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. Trends Mol Med. 2011;17(12):689–698. doi: 10.1016/j.molmed.2011.08.004.
    1. Moschetti V, Desch M, Goetz S, Liesenfeld K-H, Rosenbrock H, Kammerer KP, et al. Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 Inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study. Eur J Drug Metab Pharmacokinet. 2018;43(2):239–249. doi: 10.1007/s13318-017-0440-z.
    1. Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, et al. Multiple rising doses of oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: a randomised, double-blind, phase I study investigating safety and pharmacokinetics. Clin Drug Investig. 2018;38(8):737–750. doi: 10.1007/s40261-018-0660-2.
    1. World Medical A World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
    1. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human u. ICH harmonized tripartite guideline: guideline for Good Clinical Practice. J Postgrad Med. 2001;47(1):45–50.
    1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420. doi: 10.1023/A:1016212804288.
    1. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab. 2002;3(6):561–597. doi: 10.2174/1389200023337054.
    1. Desch M, Goettel M, Goetz S, Liesenfeld K-H, Chan T, Zhou J, et al. Effects of the potent cytochrome p450 3A4 inhibitor, itraconazole, on the pharmacokinetics of BI 425809, a new glycine transporter 1 (GlyT1) inhibitor. Clin Pharmacol Ther. 2017;101:S52. doi: 10.1002/cpt.547.
    1. Desch M. Effects of the potent cytochrome P450 3A4 inhibotor, itraconazole, on the pharmacokinetics of BI 425809, a new glycine transporter 1 (GLYT 1) inhibitor. Clin Pharmacol Ther. 2017;101(S1):S5–S99. doi: 10.1002/cpt.570.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel